June 26, 2011. Surat, India - Sahajanand Medical Technologies (SMT) announced that it has received European CE marking for two Sirolimus eluting coronary stent systems; Supralimus® (Sirolimus eluting stents on stainless steel platform) & Supralimus-Core® (Sirolimus eluting stent on chromium cobalt platform).The CE approval for Supralimus® and Supralimus-Core® brings the company the distinction of being the first in the world to have CE approval for both Sirolimus and Paclitaxel -eluting coronary stents and in total three CE approved drug eluting stents.
“The CE mark for Supralimus® and Supralimus-Core® is a significant accomplishment that substantiates our product’s excellent clinical outcomes. This further confirms our commitment to providing patients and clinicians new treatment options for coronary artery disease.” shared Dhirajlal Kotadia-CEO of Sahajanand, “The excellent flexibility, highly deliverable system and proven safety and efficacy of Sirolimus with the biodegradable polymers make our stents an excellent choice for a variety of patients” he added... [PDF] Sahajanand Medical Technologies -
